Genfit SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Genfit SA Announces Data Reporting the Efficacy and Mechanism of Action of GFT505 in Different Animal Models of NASH
Genfit SA announced the publication in Hepatology of data reporting the efficacy and mechanism of action of GFT505 in different animal models of NASH (non-alcoholic steatohepatitis). The manuscript includes data showing that GFT505 has both preventive and curative effects on hepatic steatosis, inflammation, and fibrosis. These beneficial effects are associated with an improvement in liver dysfunction markers in the blood, and with a decrease in liver expression of pro-inflammatory and pro-fibrotic genes. The results also demonstrate the interest of GFT505 as a mixed activator of the PPARa and PPARd receptors as compared to reference molecules. Moreover, a combined analysis of four Phase IIa studies performed in dyslipidemic, pre-diabetic, and/or diabetic patients confirmed the beneficial effects of GFT505 on hepatic dysfunction markers in man.
Latest Key Developments in Biotechnology
- Tekmira Pharmaceuticals Corp announces proposed public offering of common stock
- La Jolla Pharmaceutical Co reports positive, top-line results from phase 2 clinical trial of gcs-100 in chronic kidney disease
- FDA designates Regado Biosciences Inc's REG1 in PCI as a fast track development program
- Omeros Corporation announces positive OMS721 Data in Serum from patients with aHUS
- Share this
- Digg this